<DOC>
	<DOCNO>NCT00916656</DOCNO>
	<brief_summary>This multinational , multicenter , prospective , open-label historically control Phase IIIb non-inferiority clinical trial efficacy safety Fibrinogen Concentrate ( Human ) . It estimate 150-300 patient U.S. suffer afibrinogenemia . Substitution cryoprecipitate alternative treatment limit safety efficacy . The primary purpose study demonstrate hemostatic efficacy Fibrinogen Concentrate ( Human ) adequately control acute bleeding ( spontaneous trauma ) patient congenital fibrinogen deficiency ( afibrinogenemia hypofibrinogenemia ) . Cryoprecipitate hemostatic efficacy data retrospective physician survey use historical control .</brief_summary>
	<brief_title>Fibrinogen Concentrate ( Human ) âˆ’ Efficacy Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Afibrinogenemia</mesh_term>
	<criteria>Documented congenital fibrinogen deficiency ( afibrinogenemia hypofibrinogenemia ) , expect require treatment bleed Presenting episode acute bleeding ( either spontaneous trauma ) require surgery Provide inform consent Life expectancy &lt; 6 month Bleeding disorder congenital fibrinogen deficiency , include dysfibrinogenemia Treatment investigational medicinal product ( IMP ) 30 day prior enrollment Treatment fibrinogen concentrate fibrinogen contain blood product 2 week prior enrollment Treatment coagulation active drug ( i.e. , nonsteroidalantirheumatics , warfarin , cumarin derivates , platelet aggregation inhibitor ) 1 week prior enrollment plan expect medication time period Day 1 24 hour last FCH infusion Presence history hypersensitivity FCH Presence history deep vein thrombosis pulmonary embolism within 1 year prior enrollment Presence history arterial thrombosis within 1 year prior enrollment Presence history hypersensitivity human plasma protein Presence history esophageal varicose bleed End stage liver disease ( i.e. , Child Pugh score B C ) Planned expect surgery ( i.e. , bleeding aneurysm splenic rupture ) Pregnancy , intention become pregnant study Currently breastfeeding , intention breastfeeding study Human immunodeficiency virus ( HIV ) positive Polytrauma , present within 6 month prior enrollment Suspicion antifibrinogen inhibitor indicate previous invivo recovery ( IVR ) , available ( &lt; 0.5 ( mg/dL ) / ( mg/kg ) ) Previous inclusion treatment prospective part study Participation clinical study 30 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Congenital fibrinogen deficiency</keyword>
</DOC>